LOG IN/REGISTER >
FORWARD TO A COLLEAGUE >
INDICATION/SAFETY INFORMATION >

As you work to grow and improve your facility's stroke treatment, use these helpful links for ongoing education, best practices, and community news.

National stroke organizations

The Brain Attack Coalition (BAC)

This group of professional, voluntary, and governmental entities is dedicated to reducing the incidence and impact of stroke. The coalition aims to assist stroke patients and those at risk of stroke by strengthening and promoting the relationships among its member organizations.
http://www.stroke-site.org/
1-301-496-5751

The Joint Commission

The Joint Commission offers accreditation and/or certification to qualifying healthcare facilities. The site tells you how to seek stroke center certification and the process by which they review and reinstate certification.
http://www.jointcommission.org/

The Stroke Collaborative

A joint campaign of the American Academy of Neurology, the American College of Emergency Physicians, and the American Heart Association/American Stroke Association, containing professional resources.
http://www.giveme5forstroke.org
1-888-4-STROKE

The Internet Stroke Center

An educational Web site that offers information about stroke care and research.
http://www.strokecenter.org

American Stroke Association (ASA)

The ASA Web site offers information about stroke, including warning signs, general facts, and treatment. The site offers resources such as the "Get with the Guidelines" program, which helps to build primary stroke centers and improve stroke treatment quality.
http://www.strokeassociation.org
1-888-4-STROKE

National Stroke Association (NSA)

On the NSA Web site, patients can find answers to frequently asked questions, tips on prevention, and other information on stroke. Materials are also available in French and Spanish.
http://www.stroke.org
1-800-STROKES

Regional stroke networks

Northeast Cerebrovascular Consortium (NECC)

Maine, New Hampshire, Vermont, New York, Massachusetts., Rhode Island, Connecticut, and New Jersey
http://www.thenecc.org

Tri-State Stroke Network (TSSN)

Georgia, North, and South Carolina.
http://www.tristatestrokenetwork.org

Northwest Regional Stroke Network (NWRSN)

Alaska, Idaho, Montana, Oregon, and Washington.
http://www.doh.wa.gov/cfh/NWR-Stroke-Network/default.htm

Great Lakes Regional Stroke Network (GLRSN)

Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin.
http://www.uic.edu/depts/glstrknet/index.html

Additional online resources

Genentech is neither affiliated with nor endorses any of these organizations.

Indication
Activase (Alteplase) is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS).

Safety Information
Activase therapy in patients with AIS is contraindicated in certain situations (eg, suspicion of subarachnoid hemorrhage on pretreatment evaluation, recent (within 3 months) intracranial or intraspinal surgery, history of intracranial hemorrhage, uncontrolled hypertension at time of treatment, active internal bleeding, known bleeding diathesis (eg, current use of oral anticoagulants, administration of heparin within 48 hours of onset of stroke, platelet count <100,000) (see CONTRAINDICATIONS for full list).

The most common complication during Activase therapy is bleeding. Should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, Activase therapy should be discontinued immediately. Death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes.

The risks of Activase therapy may be increased and should be weighed against the anticipated benefits in certain conditions. [See WARNINGS in full prescribing information].

  • Patients with severe neurological deficit (eg, NIHSS >22) at presentation. There is an increased risk of intracranial hemorrhage in these patients.
  • Patients with major early infarct signs on a computerized cranial tomography (CT) scan (eg, substantial edema, mass effect, or midline shift).

Treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended.

Orolingual angioedema has been observed in postmarketing experience in patients treated with Activase for AIS. Patients should be monitored during and for several hours after infusion for signs of orolingual angioedema.

Please click here for full prescribing information.